MiMedx Group, Inc. (NASDAQ:MDXG) Given Average Rating of "Buy" by Brokerages

MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) has earned a consensus recommendation of "Buy" from the five brokerages that are currently covering the company, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have covered the stock in the last year is $12.00.

Separately, StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday, November 8th.

MiMedx Group Stock Performance

Shares of MDXG stock traded down $0.24 during mid-day trading on Friday, hitting $8.79. The stock had a trading volume of 501,619 shares, compared to its average volume of 535,481. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The firm has a market cap of $1.29 billion, a PE ratio of 15.98 and a beta of 1.96. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The company's 50-day simple moving average is $9.21 and its 200-day simple moving average is $7.47.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.02. The business had revenue of $84.06 million during the quarter, compared to the consensus estimate of $81.00 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. During the same quarter last year, the firm posted $0.05 EPS. Sell-side analysts anticipate that MiMedx Group will post 0.3 earnings per share for the current year.

Institutional Investors Weigh In On MiMedx Group

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in shares of MiMedx Group by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock worth $16,518,000 after acquiring an additional 44,254 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in MiMedx Group by 6.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company's stock valued at $8,483,000 after purchasing an additional 92,726 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of MiMedx Group by 47.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company's stock worth $8,958,000 after purchasing an additional 413,443 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of MiMedx Group by 299.9% during the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock worth $6,074,000 after buying an additional 770,744 shares in the last quarter. Finally, Royce & Associates LP raised its position in shares of MiMedx Group by 5.3% in the third quarter. Royce & Associates LP now owns 972,853 shares of the company's stock valued at $5,750,000 after buying an additional 48,539 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company's stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.